Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)

GlobeNewswire October 18, 2017

FibroGen Appoints Gerald Lema to Board of Directors

GlobeNewswire September 19, 2017

Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017

GlobeNewswire September 13, 2017

FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

GlobeNewswire September 5, 2017

FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock

GlobeNewswire August 15, 2017

FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock

GlobeNewswire August 14, 2017

Morgan Stanley Expects Galapagos Shares To Rise 10%

Benzinga.com  August 10, 2017

Mid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide

Benzinga.com  August 8, 2017

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 8, 2017

Mid-Day Market Update: Stocks Turn Higher; Depomed Shares Plummet

Benzinga.com  August 8, 2017

Mid-Morning Market Update: Markets Edge Lower; CVS Health Profit Tops Expectations

Benzinga.com  August 8, 2017

FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

GlobeNewswire August 7, 2017

FibroGen Reports Second Quarter 2017 Financial Results

GlobeNewswire August 7, 2017

FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017

GlobeNewswire July 31, 2017

FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer

GlobeNewswire June 21, 2017

About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

GlobeNewswire June 13, 2017

European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

GlobeNewswire June 5, 2017

FibroGen Reports First Quarter 2017 Financial Results

GlobeNewswire May 9, 2017

Investor Network: FibroGen, Inc. to Host Earnings Call

Accesswire May 9, 2017

FibroGen to Report First Quarter Financial Results on May 9, 2017

GlobeNewswire May 3, 2017